Sacubitril/valsartan-treated patients with exacerbated acute heart failure: approaches to care in the emergency department and on the ward.

Autor:	Miró Ò; Área de Urgencias, Hospital Clínic, Barcelona, Grupo de Investigación 'Urgencias: Procesos y Patologías', IDIBAPS, Universitat de Barcelona, España., Martín-Sánchez FJ; Servicio de Urgencias, Hospital Clínico San Carlos, Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, España., Jacob J; Servicio de Urgencias, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España., Herrero-Puente P; Servicio de Urgencias, Hospital Universitario Central de Asturias, Oviedo, España., Gil V; Área de Urgencias, Hospital Clínic, Barcelona, Grupo de Investigación 'Urgencias: Procesos y Patologías', IDIBAPS, Universitat de Barcelona, España., Llorens P; Servicio de Urgencias, Corta Estancia y Hospitalización a Domicilio, Hospital General de Alicante, ISABIAL - Fundación FISABIO, Alicante, Universitat Miguel Hernández, Elx, Alicante, España.
Jazyk:	Spanish; Castilian; English
Zdroj:	Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias [Emergencias] 2019 Dic; Vol. 31 (6), pp. 407-412.
Abstrakt:	Objectives: To describe the pattern of care usually given to patients with acute heart failure (AHF) who are taking sacubitril/valsartan (SV) and to explore the effects of care characteristics on clinical outcomes. Material and Methods: Exploratory study of AHF cases in patients taking SV who were included in the register for the Epidemiology of Acute Heart Failure in Emergency Departments during the sixth period of data collection (EAHFE-6). We extracted baseline and episode variables and information related to SV treatment. We also analyzed associations between the discontinuation of SV therapy and adverse events within 180 days (all-cause mortality) and after discharge (emergency revisits, admission for AHF, death from any cause, or a composite event). Results: . Fifty patients on SV were included. The median time on SV therapy was 81 days (interquartile range, 43-284 days). SV was discontinued in 19 cases (38%; 5 in the emergency department and 14 on the ward). Sixteen records specified the reason for discontinuing SV: renal insufficiency, 4 cases; arterial hypotension, 3; weakness/dizziness, 3; and exacerbated AHF, 3. SV discontinuation was associated with older age, absence of treatment with a betablocker, and hyperkalemia. The EAHFE-6 cases did not reveal significant differences related to SV discontinuation with respect to the rates of adverse events within 180 days or on discharge after the index event. Conclusion: Long-term SV therapy is discontinued in over a third of patients who present with exacerbated AHF even though no association with clinical outcomes could be identified.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu